# EDGAR Filing Document

**Accession Number:** 0001621443
**File Stem:** 0001104659-23-002058
**Filing Date:** 2023-1
**Character Count:** 27296
**Document Hash:** 415d5763b703b97e3e1957dd8ffd75e2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-002058.hdr.sgml**: 20230109

**ACCESSION NUMBER**: 0001104659-23-002058

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 50

**CONFORMED PERIOD OF REPORT**: 20230109

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230109

**DATE AS OF CHANGE**: 20230109

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zynerba Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001621443
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 260389433
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37526
- **FILM NUMBER:** 23516574

**BUSINESS ADDRESS:**
- **STREET 1:** 80 W. LANCASTER AVENUE
- **STREET 2:** SUITE 300
- **CITY:** DEVON
- **STATE:** PA
- **ZIP:** 19333
- **BUSINESS PHONE:** 484-581-7505

**MAIL ADDRESS:**
- **STREET 1:** 80 W. LANCASTER AVENUE
- **STREET 2:** SUITE 300
- **CITY:** DEVON
- **STATE:** PA
- **ZIP:** 19333

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Zynerba Pharmeceuticals, Inc.
- **DATE OF NAME CHANGE:** 20141003

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15 (d)**

**of the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): **January 9, 2023**

**ZYNERBA PHARMACEUTICALS, INC.**

(Exact Name of Issuer as Specified in Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37526** | **26-0389433** |
| (State or Other Jurisdiction of<br> Incorporation or Organization) | (Commission <br> File Number) | (I.R.S. Employer <br> Identification No.) |

---

**80 W. Lancaster Avenue, Suite 300**

**Devon, PA 19333**

(Address of Principal Executive Offices)

**(484) 581-7505**

(Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8–K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)

◻ Pre–commencement communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))

◻ Pre–commencement communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which<br> registered** |
| Common Stock, $0.001 par value per share | ZYNE | The Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 8.01 Other Events**

Attached as Exhibit 99.1 is a presentation, including certain financial information, that Zynerba Pharmaceuticals, Inc. will post on its website on January 9, 2023, and may use from time to time in presentations or discussions with investors, analysts, or other parties.

**Item 9.01** **Financial Statements and Exhibits**

The following exhibits are being filed herewith:

**(d) Exhibits**

---

| | |
|:---|:---|
| **Exhibit<br> No.** | **Document** |
| [99.1](tm232480d1_ex99-1.htm) | [Zynerba Pharmaceuticals, Inc. Presentation](tm232480d1_ex99-1.htm) |
| 104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 9, 2023

---

| | |
|:---|:---|
| **ZYNERBA PHARMACEUTICALS, INC.** | **ZYNERBA PHARMACEUTICALS, INC.** |
| By: | /s/ Albert P. Parker&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; |
|  | Name: Albert P. Parker |
|  | Title: Chief Legal Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](tm232480d1_ex99-1img001.jpg)© 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. NASDAQ ZYNE Advancing Science. Improving Connections. January 2023

![](tm232480d1_ex99-1img002.jpg)

Forward - Looking Statements The statements in this presentation may include forward - looking statements within the meaning of the private securities litigati on reform act of 1995. These statements, among other things relate to the future operations, opportunities, or financial performance of Zy nerba Pharmaceuticals, Inc. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," " est imates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," or other words that convey uncertain ty of future events or outcomes to identify these forward - looking statements. Such statements are subject to numerous important factors, risks and unce rtainties that may cause actual events or results to differ materially from the Company's current expectations, including but not limited to the following: the Company's cash and cash equivalents may not be sufficient to support its operating plan for as long as anticip ate d; the results, cost and timing of the Company's clinical development programs, including any delays to such clinical trials relatin g t o enrollment or site initiation; clinical results for the Company's product candidates may not be replicated or continue to occur in the C omp any's ongoing or planned clinical trials in FXS, 22q, or in any additional trials, and may not otherwise support further development in a s pec ified indication or at all; the Company's RECONNECT trial may not be determined to be sufficient to support a submission for regulatory approv al, including an NDA or MAA; actions or advice of the U.S. Food and Drug Administration or foreign regulatory agencies may affect th e design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; the Co mpany's ability to obtain and maintain regulatory approval for its product candidates, and the labeling under any such approval; the Company's e xpe ctations regarding its ability to obtain and adequately maintain sufficient intellectual property protection for its product candidate s; the extent to which health epidemics or other outbreaks of communicable diseases, including COVID - 19, could disrupt our operations or adversel y affect our business and financial conditions; and the extent to which inflation or global instability, including political in sta bility, may disrupt our business operations or our financial condition. These and other risks are described in our filings with the U.S. Securities and Exchange Commission, available at www.sec.gov. Any forward - looking statements that the Company makes in this presentation speak only as o f the date of this presentation. The Company assumes no obligation to update forward - looking statements whether as a result of new information, future events or otherwise, after the date of this presentation . January 2023 Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 2© 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. A ll other trademarks are property of their respective owners.

![](tm232480d1_ex99-1img003.jpg)

A different and exciting approach to Cannabidiol

![](tm232480d1_ex99-1img004.jpg)

An Orphan - Focused Neuropsychiatric, Biopharmaceutical Company Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 4 Permeation - enhanced Patent - protected through 2040 Pharmaceutically manufactured; THC free FIRST AND ONLY TRANSDERMAL CANNABIDIOL GEL One Phase 3 clinical program ongoing One additional orphan indication is Phase 3 ready LATE - STAGE PIPELINE Leadership expertise in transdermal delivery, rare diseases and specialty markets POSITIONED FOR SUCCESS A different and exciting approach to Cannabidiol January 2023

![](tm232480d1_ex99-1img005.jpg)

Benefits of Our Approach to Cannabidiol Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 5 FDA regulated Consistency of production Purity of ingredients No THC – not a scheduled drug by U.S. DEA Scalable production process PHARMACEUTICAL MANUFACTURING PHARMACEUTICAL DISPENSARY Ease of application for caregivers of patients with behavioral issues Minimizes GI side effects and reduces risk for liver toxicity Lower risk for drug/drug interactions Avoids conversion to THC in stomach Provides cannabidiol plasma levels similar to oral cannabidiol (5 - 10 mg/ kg) plasma levels TRANSDERMAL DELIVERY January 2023

![](tm232480d1_ex99-1img006.jpg)

• Cannabidiol pre - dose concentrations in adults with epilepsy receiving either 195 mg/day or 390 mg/day of Zygel ranged from 0.72 ng/mL to 77.50 ng/mL • Cannabidiol pre - dose concentrations peaked at 235 ng/mL in adults who received Zygel in doses ranging from 390 mg/day to 780 mg/day in the open - label extension phase of the trial • The concentrations achieved overlap those reported with oral cannabidiol (5 - 10 mg/kg/day) • Consistent with trials of oral cannabidiol, substantial variation in interindividual and intraindividual plasma concentrations was reported • THC was not detected in the plasma January 2023 Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 6 Transdermal Administration of Cannabidiol Successfully Achieved Plasma Concentrations that Overlap Those Reported with Oral Cannabidiol (5 - 10mg/kg) Source: O'Brien TJ et al. JAMA Netw Open. 2022;5(7):e2220189. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2794028

![](tm232480d1_ex99-1img007.jpg)

Clinical Development Programs Fragile X Syndrome FXS 22q Deletion Syndrome 22q

![](tm232480d1_ex99-1img008.jpg)

Overlap of Symptoms Across Conditions Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 8 Anxiety Seeks Isolation Social Avoidance Lack of Interaction Attention Deficits Irritability FXS 22q January 2023

![](tm232480d1_ex99-1img009.jpg)

Fragile X Syndrome (FXS) Focused Clinical Pipeline Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 9 Preclinical Phase 1 Phase 2 Pivotal Market 22q Deletion Syndrome (22q) Regulatory Filing U.S. Orphan Drug and Fast Track designations; EU Orphan Drug designation U.S. Orphan Drug designation; EU Orphan Drug designation Zygel TM (ZYN002 Cannabidiol Gel) January 2023

![](tm232480d1_ex99-1img010.jpg)

• Majority of treatment - emergent AEs (TEAEs) were mild or moderate • Most common Zygel - related • No clinically significant changes in vital signs or ECGs • No Zygel - related clinically significant changes in laboratory values, including liver function tests Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 10 Well - Tolerated Safety Profile

![](tm232480d1_ex99-1img011.jpg)

Fragile X Syndrome

![](tm232480d1_ex99-1img012.jpg)

~78K U.S. PATIENTS What is Fragile X Syndrome (FXS)? Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 12 • Leading known cause of inherited intellectual disability and autism spectrum disorder • Mutation of the FMR1 gene causes endocannabinoid system (ECS) dysregulation • Easily identified mutation manifests as multiple CGG repeats FMR1 (full mutation >200 repeats) • Resulting in cognitive, social, and behavioral symptoms • Behavioral Symptoms linked to deficiencies in the ECS WITH FXS EU/UK PATIENTS U.S. & EU Orphan Drug Designation Granted for FXS January 2023

![](tm232480d1_ex99-1img013.jpg)

Poised for Success in FXS Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 13 Largest clinical trial ever conducted in children with FXS Extensive safety database Patients on drug for up to five years Statistically significant outcomes in children with complete methylation Lessons Learned from Previous Trials Improve Probability of Success in RECONNECT Pivotal Trial January 2023

![](tm232480d1_ex99-1img014.jpg)

Role of FMR1 Methylation in FXS Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 14 • FMR1 gene codes for production of FMRP\* which is vital to synapse development • Methylation of the FMR1 gene plays a role in determining gene function • When methylation of the FMR1 gene silences the gene, no FMRP is produced: • Systems and processes affected by FMRP become dysregulated • ~60% of FXS patients are believed to be completely methylated • Completely methylated patients are the most severely impacted ~47K U.S. PATIENTS WITH COMPLETE METHYLATION EU/UK PATIENTS \*RNA - binding protein that helps regulate synaptic development and plasticity January 2023

![](tm232480d1_ex99-1img015.jpg)

CONNECT - FX Trial Key Learning: Results with complete methylation of FMR1 gene Consistent Improvements Observed with Zygel vs. Placebo in Patients with Complete Methylation Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 15 PRIMARY ENDPOINT CAREGIVER REPORTED BEHAVIOR CHANGE CLINICIAN REPORTED BEHAVIOR IMPROVEMENTS CLINICALLY MEANINGFUL BEHAVIOR IMPROVEMENTS ABC - C FXS Social Avoidance Subscale Caregiver Global Impression of Change (ZYGEL vs Placebo) Clinical Global Impression of Improvement (anchored)\*\* More Patients Achieved Meaningful Change (ZYGEL vs Placebo) Ad hoc analysis of 136 patients with complete methylation \*Statistically significant , Not specific to Social Avoidance 40% median percent improvement in socially avoidant behaviors (p =0.027\*) SOCIAL INTERACTION 63% vs 37% (p =0.005\*) IRRITABLE/DISRUPTIVE BEHAVIORS 54% vs 33% (p =0.027\*) SOCIAL AVOIDANCE/ISOLATION 58% vs 46% (p =0.195) OVERALL BEHAVIOR 61% vs 46% (p =0.100) ANY IMPROVEMENT Zygel vs placebo 50% vs 36% (p =0.128) SOCIAL AVOIDANCE (≥ 3 POINTS) 56% vs 37% (p =0.030\*) IRRITABILITY (≥ 9 POINTS) 37% vs 26% (p =0.232) January 2023

![](tm232480d1_ex99-1img016.jpg)

Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 16 Clinically Meaningful Improvement a Achieved and Maintained in Patients with Complete Methylation b 0 10 20 30 40 50 60 70 80 90 100 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Cumulative Percentage of Patients Month Zygel (n=47) Placebo (n=49) Switch from Placebo to Zygel CONNECT - FX Double - Blind c a. Meaningful change in Social Avoidance: ≥3 - point improvement from baseline; maintained for ≥ 2 consecutive visits b. Patients matching primary efficacy population in RECONNECT c. ZYN2 - CL - 016 (CONNECT - FX) Percentage of patients with clinically meaningful improvement in ABC - C FXS Social Avoidance January 2023

![](tm232480d1_ex99-1img017.jpg)

CONNECT - FX Data Published in the Journal of Neurodevelopmental Disorders Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 17 • "…ZYN002 was well tolerated in patients with FXS and demonstrated evidence of efficacy with a favorable benefit risk relationship in patients with ≥ 90% methylation of the FMR1 gene, in whom gene silencing is most likely, and the impact of FXS is typically most severe." • "Thus, CONNECT - FX appears to provide evidence that identifies a biologically identifiable and clinically responsive population of patients affected by FXS who are defined by both full mutation and ≥ 90% methylation of the FMR1 gene." The article can be accessed online at the Journal of Neurodevelopmental Disorders at https://rdcu.be/c0sKz . January 2023

![](tm232480d1_ex99-1img018.jpg)

Design Optimized from CONNECT - FX Trial Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 18 More patient and family friendly Extending trial to 18 - weeks Increased dosing option for individuals >50 kg Successful completion of Phase 3 pivotal trial expected to satisfy requirements for an NDA submission in the U.S. and a marketing authorization application in the EU. Primary endpoint: Patients with complete methylation January 2023

![](tm232480d1_ex99-1img019.jpg)

Confirmatory Pivotal Trial Design Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 19 Double - Blind, Placebo - Controlled Study: Initiated 18 weeks Zygel (n~100; 80\*) 250 mg daily (≤30kg) 500 mg daily (>30kg) 750 mg daily (>50kg) (weight - based dose) Placebo (n~100; 80\*) Mirrors Zygel administration \*Patients with complete methylation of FMR1 gene Patients randomized (1:1) to receive either Zygel or placebo Open Label Extension (OLE): Ongoing 24 months All patients receive Zygel January 2023

![](tm232480d1_ex99-1img020.jpg)

Trial Objectives Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 20 Change from baseline to end of treatment in ABC - C FXS Social Avoidance subscale in patients who have complete (100%) methylation of their FMR1 gene • Change from baseline to end of treatment in: • ABC - C FXS Irritability subscale in patients who have complete methylation • ABC - C FXS Social Avoidance subscale among all randomized patients (complete and partial methylation) • Percent of patients: • With any improvement on the Caregiver Global Impression of Change (CaGI - C) for Social Interactions among patients with complete methylation • Rated as improved on the Clinical Global Impression - Improvement (CGI - I) scale among patients with complete methylation SECONDARY ENDPOINTS PRIMARY ENDPOINT January 2023

![](tm232480d1_ex99-1img021.jpg)

Next Steps in FXS Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 21 Continued RECONNECT pivotal trial enrollment Topline results expected in 1H 2024 January 2023

![](tm232480d1_ex99-1img022.jpg)

22q11.2 Deletion Syndrome (22q) Image courtesy Positive Exposure© 2016 Positive Exposure. All rights reserved. www.PositiveExposure.org . Eliza, living with 22q11.2 deletion syndrome

![](tm232480d1_ex99-1img023.jpg)

What is 22q11.2 Deletion Syndrome (22q)? Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 23 • Rare disorder and second most common genetic disorder, behind Down yndrome • Midline condition with abnormalities affecting palate, face, heart and other organs; surgically corrected in infancy • Neuropsychiatric illnesses and learning disabilities common • Early onset of neuropsychiatric symptoms disrupts development and quality of life, and heightens risk of later psychotic disorders • No drugs currently approved WITH 22q ~83K U.S. PATIENTS ~129K EU/UK PATIENTS January 2023

![](tm232480d1_ex99-1img024.jpg)

U.S. & EU ORPHAN DRUG DESIGNATION GRANTED FOR TREATMENT OF 22q Rationale for Zygel in 22q Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 24 • Overlapping symptoms with FXS and ASD • Associated with increased anxiety, irritability, social withdrawal and social interaction problems • Cannabidiol may treat neurop sychiatric symptoms due to activity as: • Modulator of ECS • Agonist at serotonin 1A receptors • Antagonist at GPR55 receptors January 2023

![](tm232480d1_ex99-1img025.jpg)

INSPIRE Phase 2 Trial Design Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 25 Period 1: Completed 14 weeks Zygel (n = 20) 250 mg daily (≤35kg) 500 mg daily (>35kg) (weight - based dose) Period 2: Completed 24 weeks Efficacy assessments include: (week 14 vs baseline) • Anxiety, Depression and Mood Scale (ADAMS) • Aberrant Behavior Checklist - Community (ABC - C) • Pediatric Anxiety Rating Scale - Revised (PARS - R) • Clinical Global Impression — Severity and Improvement (n = 13 of 17 Period 1 Completers) January 2023

![](tm232480d1_ex99-1img026.jpg)

• Statistically significant improvements at 14 weeks and 38 weeks of treatment compared to baseline for multiple efficacy assessments: • The total score and all five subscales of the Anxiety, Depression and Mood Scale (ADAMS) • All five subscales of the Aberrant Behavior Checklist – Community (ABC - C) • Pediatric Anxiety Rating Scale - Revised (PARS – R) • The majority of patients showed clinically meaningful improvements at week 14 as demonstrated by the Clinical Global Impression – Improvement (CGI - I) • Seventy - five percent of patients were rated by the clinicians as "improved", "much improved" or "very much improved" • Nearly two - thirds (62.5%) of the patients being "much improved" or "very much improved" • Zygel was shown to be well tolerated over 38 weeks, and the safety profile was consistent with previously reported data from other Zygel clinical trials • Three patients reported treatment related adverse events which were all mild application site adverse events • Three patients experienced a serious adverse event unrelated to Zygel • One patient discontinued treatment due to adverse events not related to Zygel 26 Positive Topline Results from INSPIRE Trial Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. January 2023

![](tm232480d1_ex99-1img027.jpg)

27 Efficacy: Significant Improvement in Anxiety as Measured by the PARS - R 14.7 8.5 0 2 4 6 8 10 12 14 16 PARS - R score 40.6% (P =.0005) Baseline (n=15) Week 14 (n=15) 15.3 7.4 0 2 4 6 8 10 12 14 16 PARS - R score 49.4% (P =.0001) Baseline (n=11) Week 38 (n=11) The efficacy analysis for Period 1 included 15 patients for PARS - R (2 patients did not have valid assessments at Week 14). The efficacy analysis for Period 2 included 11 patients; One patient discontinued the trial prior to week 38 and one patient who completed Week 38 stopped drug prior to completion. Improvement Improvement • The PARS - R is a clinical interview that assesses symptoms of anxiety and generates a composite score for: • Overall frequency of anxiety symptoms • Overall severity of anxiety feelings • Overall avoidance of anxiety - provoking situations • Interference with family relationships and/or performance at home • Interference with peer and adult relationships and/or performance outside of home • At Baseline, patients had clinically significant moderate anxiety on average (PARS - R=15) • At Weeks 14 and 38, patients had improved to minimal to mild anxiety on average (PARS - R=5 - 10) Period 1 14 weeks Period 2 38 weeks Mean Scores and Percentage Improvement January 2023

![](tm232480d1_ex99-1img028.jpg)

28 Efficacy: Significant Improvements in ADAMS Total and Subscale Scores Mean Scores and Percentage Improvement Period 1 14 weeks 36.1 10.4 7.6 8.7 3.0 7.6 17.7 5.1 3.4 4.3 1.1 4.4 0 5 10 15 20 25 30 35 40 Baseline (n=16) Week 14 (n=16) ADAMS total and subscale scores 45.3% (P =.0005) 43.6% (P= .0005) 50.3% (P= .0033) 64.0% (P= .0037) 41.3% (P= .0084) 38.2% (P= .0032) Improvement 36.1 11.5 7.8 9.6 2.8 7.6 15.9 4.7 2.8 4.5 0.7 3.8 0 5 10 15 20 25 30 35 40 Baseline (n=11) Week 38 (n=11) 56.6% (P =.0064) 55.1% (P= .0009) 64.5% (P= .0219) 81.4% (P= .0124) 33.5% (P= .0191) 54.4% (P= .0061) ADAMS total and subscale scores Period 2 38 weeks Improvement The efficacy analysis for Period 2 included 11 patients; One patient discontinued the trial prior to week 38 and one patient who completed Week 38 stopped drug prior to completion. Total Score and Obsessive/Compulsive Behavior N=10 as the score for one item was missing at Week 38 The efficacy analysis for Period 1 included 16 patients for ADAMS (1 patient did not have a valid assessment at Week 14). January 2023

![](tm232480d1_ex99-1img029.jpg)

29 Efficacy: Significant Improvements in All ABC - C Subscale Scores ABC - C subscale score 36.3% (P =.0055) 18.3% (P= .0166) 52.1% (P= .0155) 16.5% (P= .0091) 27.6% (P= .011) 41.6% (P =.0087) 63.3% (P= .0028) 73.3% (P= .0270) 48.1% (P= .0232) 59.4% (P= .0174) ABC - C subscale score Period 1 14 weeks Period 2 38 weeks Improvement Improvement Mean Scores and Percentage Improvement The efficacy analysis for Period 2 included 11 patients. One patient discontinued the trial prior to week 38 and one patient who completed Week 38 stopped drug prior to completion The efficacy analysis for Period 1 included 16 patients for ABC - C (1 patient did not have a valid assessment at Week 14). January 2023

![](tm232480d1_ex99-1img030.jpg)

Next Steps in 22q Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 30 Ongoing discussions with FDA regarding regulatory pathway Initiate Phase 3 program after RECONNECT topline results January 2023

![](tm232480d1_ex99-1img031.jpg)

Positioned for Success

![](tm232480d1_ex99-1img032.jpg)

Leadership Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 32 Armando Anido Chairman of the Board and CEO Terri B. Sebree President Jim Fickenscher CFO and VP, Corporate Development Paul Kirsch VP, Regulatory Affairs and Quality Assurance Joe Apostolico VP, Human Resources Terry Hurst GM, Zynerba Pharmaceuticals Pty Ltd (Australia) Stephen O'Quinn, PharmD VP, Medical Affairs Albert P. Parker Chief Legal Officer Brian Rosenberger VP, Commercial and Business Development Nancy Tich, Ph.D. VP, Clinical Ray Mannion VP, Manufacturing Carol O'Neill VP, Development January 2023

![](tm232480d1_ex99-1img033.jpg)

Financial Strength Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 33 CASH AND CASH EQUIVALENTS $55.9M as of September 30, 2022; expected to be sufficient to fund operations and capital requirements to mid - year 2024 BALANCE SHEET CLEAN No debt, 47.1M shares outstanding (as of November 9, 2022) January 2023

![](tm232480d1_ex99-1img034.jpg)

A Year of Clinical Progress Ahead Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 34 Pivotal trial results expected in 1H 2024 Finalize regulatory pathway with FDA in 2023; Initiate Phase 3 after RECONNECT topline results January 2023

![](tm232480d1_ex99-1img035.jpg)

• Leader in transdermal cannabidiol delivery • Late - stage clinical company with two orphan CNS programs in areas of high unmet need • Launch Zygel in FXS via strategic partners in EU and other Territories • Launch Zygel into additional multi - billion $ market of 22q • Optimize Zygel growth with additional synergistic indications • Accelerate further growth through complimentary asset licensing and acquisition …and Beyond Zynerba Today… …in 2026 Zynerba Vision for Future Growth Zynerba Pharmaceuticals \| Advancing Science. Improving Connections. 35 • Launch Zygel for FXS into a $1.9B+ U.S. market opportunity • Establish a fully integrated organization with U.S. commercial presence • Prepare for EU approval in FXS • Advance 22q Ph3 program towards completion January 2023

![](tm232480d1_ex99-1img036.jpg)

A different and exciting approach to Cannabidiol

![](tm232480d1_ex99-1img037.jpg)© 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. NASDAQ ZYNE Thank you!